Non-invasive screening for 28 mutations

Colorectal cancer, or bowel cancer, is the third most common type of cancer in North America, Northern Europe and Western Europe.  Colorectal cancer is rare before the age of 40.  With regular screening from 50 years, pre-cancerous lesions and polyps can be detected and removed before they can become cancerous.  Even when colorectal cancer is only detected at an advanced stage, there are a number of treatment options.

Stool DNA (sDNA) screening has the potential to offer a non-invasive yet highly specific screening method to identify high risk individuals that would benefit the most from a colonoscopy.  The RanplexCRC array tests colorectal cells that have been shed into the stool for 28 mutations common in colorectal cancer and pre-cancerous growths.  The screening test is performed on a single stool sample, without the need for any patient preparation. 

The RanplexCRC Colorectal Cancer array is designed for use with the Evidence Investigator.